The presence of fQRS is a predictor in ST-elevation myocardial infarction patients undergoing p-PCI. The occurrence of fQRS is beneficial to identify the patients with severe coronary lesion, left ventricular contraction dysfunction, and larger areas of ischemic injury.
Patients with nonobstructive coronary
artery disease (NOCAD) have
high risk associated with acute myocardial infarction (AMI), and fragmented
QRS (fQRS) has a predictive value of AMI after percutaneous coronary
intervention (PCI). A cohort of 254 participants were recruited including
136 NOCAD and 118 AMI patients from Xi’an No. 1 Hospital. Comprehensive
metabolomics was performed by UPLC-Q/TOF-MS with multivariate statistical
analyses. Hazard ratios were measured to discriminate the prognostic
in AMI after PCI between differential metabolites and fQRS. OPLS-DA
separated metabolites from NOCAD and AMI in serum. A total of 23 differential
metabolites were identified between NOCAD and AMI. In addition, four
differential metabolites, namely, acetylglycine, threoninyl-glycine,
glutarylglycine, and nonanoylcarnitine, were identified between fQRS
and non-fQRS in AMI. The hazard ratios demonstrate that the metabolites
were associated with the risk of cardiac death, recurrent angina,
readmissions, and major adverse cardiovascular events, which may clarify
the mechanism of fQRS as a predictor in the prognostic of AMI after
PCI. This study identified novel differential metabolites to distinguish
the difference from NOCAD to AMI and clarify the mechanism of fQRS
in prognostic of AMI after PCI, which may provide novel insights into
potential risks and prognostic of AMI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.